This free one hour webinar took place on February 17, 2015 and was open to anyone interested in gaining a better understanding of Subsequent Entry Biologics and how these drugs impact breast cancer treatment.
SEBs, also known as biosimilars, are biologic drugs similar to an innovator product previously approved by Health Canada. Because the new drug is a biologic, it is not exactly the same as the drug it may replace.
We anticipate that SEB’s will be introduced into breast cancer treatment in about five years when Herceptin comes off patent.
SEBs have been part of the arthritis community for a number of years now. In the webinar, arthritis advocate Cheryl Koehn will explain how the arthritis community has dealt with SEBs and what we can expect once SEBs for breast cancer enter the marketplace.